Ozempic Tablets: Oral Semaglutide (Rybelsus), Dosing, and How It Compares to Injections

A common patient question is whether Ozempic comes in tablet form.

The answer is nuanced: Ozempic itself is available only as a subcutaneous injection, but the same active ingredient (semaglutide) is available orally under the brand name Rybelsus.

Key distinctions:

• Ozempic: injectable semaglutide, doses 0.25 mg, 0.5 mg, and 1 mg, once weekly
• Rybelsus: oral semaglutide, doses 3 mg, 7 mg, and 14 mg, once daily
• Both are manufactured by Novo Nordisk
• Both contain semaglutide as the active pharmaceutical ingredient
• They are not interchangeable without prescriber supervision due to different dosing schedules, bioavailability, and titration protocols

Licensing in the UK:

• Rybelsus received MHRA approval for type 2 diabetes in April 2020
• NICE TA 868 recommended Rybelsus as an option for type 2 diabetes when a GLP-1 receptor agonist is appropriate and the patient prefers oral administration
• Rybelsus is not licensed for weight management. Only Wegovy (semaglutide 2.4 mg injection) holds this indication

Why a tablet version was developed:

Peptide drugs are traditionally injectable because stomach acid and digestive enzymes destroy them.

Novo Nordisk developed a novel absorption technology to overcome this barrier, making semaglutide the first GLP-1 receptor agonist available in oral form.

Rybelsus co-formulates semaglutide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that enables the peptide to cross the gastric mucosa.

SNAC mechanism of action:

• SNAC creates a localised increase in pH at the tablet surface, protecting semaglutide from pepsin degradation
• It promotes transcellular absorption of semaglutide across the gastric epithelium via a concentration-dependent, passive process
• Absorption occurs primarily in the stomach, not the small intestine. This is why the tablet must be taken on an empty stomach
• SNAC is metabolised and excreted without systemic pharmacological effects

Bioavailability considerations:

• Oral semaglutide has a bioavailability of approximately 0.4 to 1%, compared to 89% for subcutaneous injection
• This means the oral doses (3 mg, 7 mg, 14 mg) are much higher in milligram terms than the injectable doses (0.25 mg, 0.5 mg, 1 mg) to achieve comparable plasma levels
• Oral bioavailability is highly variable between patients and within the same patient on different days. Food, water volume, and timing dramatically affect absorption

Strict administration requirements:

• Take on an empty stomach after an overnight fast (at least 6 hours without food)
• Swallow whole with up to 120 mL (half a glass) of plain water only
• Wait at least 30 minutes before eating, drinking other liquids, or taking other oral medications
• Do not crush, chew, or split the tablet

Failure to follow these instructions significantly reduces absorption and therapeutic efficacy.

Like Ozempic, Rybelsus follows a titration schedule to minimise GI side effects. The steps differ from the injectable product.

Step 1: 3 mg once daily for 30 days

This is a titration dose only. It does not provide clinically meaningful glucose lowering. Its purpose is GI adaptation.

Do not extend this phase beyond 30 days as the 3 mg dose has no therapeutic benefit.

Step 2: 7 mg once daily (first maintenance dose)

After 30 days at 3 mg, increase to 7 mg daily. The PIONEER trials showed this dose reduces HbA1c by approximately 10 to 13 mmol/mol (1.0 to 1.3%).

Step 3: 14 mg once daily (maximum dose)

If additional glycaemic control is needed after at least 30 days on 7 mg, increase to 14 mg. This dose provides HbA1c reductions of approximately 13 to 16 mmol/mol (1.3 to 1.

5%) and the greatest weight loss of the oral doses.

Comparison of approximate HbA1c reduction by product and dose:

• Rybelsus 7 mg daily: 10 to 13 mmol/mol
• Rybelsus 14 mg daily: 13 to 16 mmol/mol
• Ozempic 0.5 mg weekly: 12 mmol/mol
• Ozempic 1 mg weekly: 16 to 18 mmol/mol

The injectable 1 mg dose achieves modestly greater HbA1c reduction than the maximum oral 14 mg dose, likely reflecting the higher and more consistent bioavailability of subcutaneous administration.

• Do not take two 7 mg tablets to substitute for one 14 mg tablet. The absorption kinetics differ
• If a dose is missed, skip it and take the next dose at the usual time the following day

The PIONEER programme evaluated oral semaglutide across 10 Phase 3 trials in various clinical settings.

PIONEER 1 (monotherapy, 26 weeks):

• Rybelsus 14 mg: HbA1c reduction of 13 mmol/mol (1.5%), weight loss of 3.7 kg
• Placebo: HbA1c reduction of 1 mmol/mol (0.1%), weight loss of 1.4 kg

PIONEER 2 (vs empagliflozin 25 mg, added to metformin, 52 weeks):

• Rybelsus 14 mg: HbA1c reduction of 13 mmol/mol (1.3%), weight loss of 3.8 kg
• Empagliflozin 25 mg: HbA1c reduction of 9 mmol/mol (0.9%), weight loss of 3.7 kg
• Rybelsus was statistically superior for HbA1c with comparable weight loss

PIONEER 4 (vs liraglutide 1.8 mg, added to metformin, 52 weeks):

• Rybelsus 14 mg: HbA1c reduction of 12 mmol/mol (1.2%), weight loss of 4.4 kg
• Liraglutide 1.8 mg: HbA1c reduction of 11 mmol/mol (1.1%), weight loss of 3.1 kg
• Rybelsus was non-inferior for HbA1c and produced greater weight loss

PIONEER 7 (flexible dosing in real-world-like setting, 52 weeks):

• Demonstrated that dose adjustments based on HbA1c response at clinic visits are practical and effective

Across the programme, oral semaglutide 14 mg showed efficacy comparable to many injectable GLP-1 agonists, though the injectable semaglutide 1 mg (Ozempic) retains a modest advantage in head-to-head modelled comparisons due to higher bioavailability.

The choice between Ozempic (injection) and Rybelsus (tablet) involves clinical effectiveness, patient preference, and practical factors.

Reasons to prefer Rybelsus (oral):

• Needle phobia or strong aversion to injections. This is a common and valid concern
• Patient preference for daily oral medication over weekly injection
• Patients who travel frequently and find injection storage and sharps disposal inconvenient
• Those who prefer to avoid subcutaneous nodules or injection site reactions

Reasons to prefer Ozempic (injection):

• Greater and more consistent HbA1c reduction at maximum dose (1 mg weekly vs 14 mg daily)
• Greater weight loss, which matters if weight management is a treatment goal
• Once-weekly dosing suits patients who prefer fewer medication events
• No fasting requirement. Ozempic can be injected at any time regardless of meals
• More predictable absorption. Rybelsus absorption varies with food and water intake
• Patients already taking multiple morning medications who cannot maintain the 30-minute fasting window

Cost considerations:

NICE TA 868 assessed Rybelsus as cost-effective at the manufacturer's confidential price. NHS Drug Tariff prices vary, and local formulary decisions may favour one formulation.

Your prescriber can advise on local availability.

Switching between formulations:

Patients can switch from Rybelsus to Ozempic (or vice versa) under prescriber guidance. There is no mandatory washout period. When switching from Rybelsus 14 mg to Ozempic, starting at 0.

5 mg weekly is generally appropriate.

Rybelsus availability in the UK has improved since its initial launch, though regional variation exists.

NHS prescribing pathway:

• Rybelsus is available on NHS prescription for type 2 diabetes
• NICE TA 868 (published August 2023) recommends oral semaglutide as an option when a GLP-1 receptor agonist is appropriate and an oral formulation is preferred
• Local Clinical Commissioning Group (now Integrated Care Board) formularies may have specific criteria or require prior authorisation
• Specialist initiation may be required in some areas, though GP continuation prescribing is standard

Supply status:

• Rybelsus supply has been more stable than Ozempic, partly because demand for the injectable product has been driven by off-label weight loss prescribing
• Novo Nordisk periodically issues supply notifications through the DHSC. Check the Specialist Pharmacy Service or your local pharmacy for current availability
• All three strengths (3 mg, 7 mg, 14 mg) must be available for safe titration. Do not start a patient on Rybelsus if the 7 mg or 14 mg tablets cannot be reliably sourced

Private prescribing:

• Rybelsus is available through private clinics and online prescribing services
• Monthly costs for private prescriptions typically range from 50 to 120 pounds depending on dose and supplier
• Patients obtaining Rybelsus privately should still have regular diabetes reviews with their NHS GP or specialist

Both Ozempic and Rybelsus require a prescription. Neither is available over the counter in the UK.

Patients should be cautious about purchasing semaglutide from unregulated online sources, as counterfeit products have been identified by the MHRA.